ArticleThe journal of allergy and clinical immunology. In practice2020
Symptom assessment in hypereosinophilic syndrome: Toward development of a patient-reported outcomes tool.
Article in The journal of allergy and clinical immunology. In practice, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 16 citations in OpenAlex.
- Benralizumab versus placebo for hypereosinophilic syndrome: a randomized, placebo-controlled phase 3 trial.Nature medicine · 2026Trial
- Characterization of disease flares and impact of mepolizumab in patients with hypereosinophilic syndrome.Frontiers in immunology · 2022Trial
- Development of a Patient-Reported Outcome Measure for Hypereosinophilic Syndrome.The journal of allergy and clinical immunology. In practice · 2025Article
- Burden of hypereosinophilic syndromes in the United States: Patients' perspective.The journal of allergy and clinical immunology. Global · 2025Article
- Biologic therapy in rare eosinophil-associated disorders: remaining questions and translational research opportunities.Journal of leukocyte biology · 2024Review
- HES and EGPA: Two Sides of the Same Coin.Mayo Clinic proceedings · 2023Review
- The multidisciplinary approach to eosinophilia.Frontiers in oncology · 2023Review
- Mepolizumab therapy improves the most bothersome symptoms in patients with hypereosinophilic syndrome.Frontiers in medicine · 2023Article
- Hypereosinophilic syndrome with multiorgan involvement: an interdisciplinary work-up.BMJ case reports · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 5 institutions in 2 countries.
Funding
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.